MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 464676 | Name: Hirudin TFA salt
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Hirudin (54-65; non-sulfated) is a desulfated peptide fragment of hirudin, an anticoagulant produced by H. medicinalis. It inhibits fibrin clot formation induced by isolated bovine thrombin with an IC50 value of 3.7 µM.

Chemical Structure

Hirudin TFA salt
Hirudin TFA salt
CAS#unknown

Theoretical Analysis

MedKoo Cat#: 464676

Name: Hirudin TFA salt

CAS#: unknown

Chemical Formula: C68H94F3N13O27

Exact Mass: 1581.6334

Molecular Weight: 1582.56

Elemental Analysis: C, 51.61; H, 5.99; F, 3.60; N, 11.51; O, 27.30

Price and Availability

Size Price Availability Quantity
1mg USD 250.00 2 Weeks
5mg USD 450.00 2 Weeks
10mg USD 750.00 2 Weeks
25mg USD 1,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Hirudin TFA salt; H-GDFEEIPEEYLQ-OH; H-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-Gln-OH;
IUPAC/Chemical Name
glycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-L-leucyl-L-glutamine, trifluoroacetate salt
InChi Key
HDWCTUMRNNNDOF-YSWJBEFPSA-N
InChi Code
InChI=1S/C66H93N13O25.C2HF3O2/c1-5-34(4)55(78-59(96)41(21-26-53(89)90)71-56(93)38(18-23-50(83)84)72-61(98)44(29-35-10-7-6-8-11-35)77-63(100)46(31-54(91)92)69-49(82)32-67)65(102)79-27-9-12-47(79)64(101)73-40(20-25-52(87)88)57(94)70-39(19-24-51(85)86)58(95)76-45(30-36-13-15-37(80)16-14-36)62(99)75-43(28-33(2)3)60(97)74-42(66(103)104)17-22-48(68)81;3-2(4,5)1(6)7/h6-8,10-11,13-16,33-34,38-47,55,80H,5,9,12,17-32,67H2,1-4H3,(H2,68,81)(H,69,82)(H,70,94)(H,71,93)(H,72,98)(H,73,101)(H,74,97)(H,75,99)(H,76,95)(H,77,100)(H,78,96)(H,83,84)(H,85,86)(H,87,88)(H,89,90)(H,91,92)(H,103,104);(H,6,7)/t34-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,55-;/m0./s1
SMILES Code
NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC2=CC=C(O)C=C2)C(N[C@H](C(N[C@@H](CCC(N)=O)C(O)=O)=O)CC(C)C)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC1)=O)[C@H](CC)C)=O)CCC(O)=O)=O)CCC(O)=O)=O)CC3=CC=CC=C3)=O)CC(O)=O)=O.FC(C(O)=O)(F)F
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
DMF 1.0 0.68
DMSO 1.0 0.68
PBS (pH 7.2) 1.0 0.68
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 1,582.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Junren C, Xiaofang X, Huiqiong Z, Gangmin L, Yanpeng Y, Xiaoyu C, Yuqing G, Yanan L, Yue Z, Fu P, Cheng P. Pharmacological Activities and Mechanisms of Hirudin and Its Derivatives - A Review. Front Pharmacol. 2021 Apr 16;12:660757. doi: 10.3389/fphar.2021.660757. PMID: 33935784; PMCID: PMC8085555. 2: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Lepirudin. 2020 Nov 16. PMID: 30000058. 3: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Desirudin. 2020 Nov 16. PMID: 29999832. 4: Saunders H, Sanghavi D. Continuous Renal Replacement Therapy. 2020 Jul 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 32310488. 5: Lemke S, Vilcinskas A. European Medicinal Leeches-New Roles in Modern Medicine. Biomedicines. 2020 Apr 27;8(5):99. doi: 10.3390/biomedicines8050099. PMID: 32349294; PMCID: PMC7277884. 6: Juhász J, Gáspári Z, Pongor S. Structure and Oxidative Folding of AAI, the Major Alfa-Amylase Inhibitor From Amaranth Seeds. Front Chem. 2020 Mar 17;8:180. doi: 10.3389/fchem.2020.00180. PMID: 32257998; PMCID: PMC7090091. 7: Goswami D, DiGiusto M, Wadia R, Barnes S, Schwartz J, Steppan D, Nelson- McMillan K, Ringel R, Steppan J. The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite. J Cardiothorac Vasc Anesth. 2020 Aug;34(8):2215-2223. doi: 10.1053/j.jvca.2020.01.020. Epub 2020 Jan 21. PMID: 32127273; PMCID: PMC7321892. 8: Erdoes G, Ortmann E, Martinez Lopez De Arroyabe B, Reid C, Koster A. Role of Bivalirudin for Anticoagulation in Adult Perioperative Cardiothoracic Practice. J Cardiothorac Vasc Anesth. 2020 Aug;34(8):2207-2214. doi: 10.1053/j.jvca.2019.08.022. Epub 2019 Aug 21. PMID: 31521492. 9: Tu Y, Hu L, Yang C, Nemat A, Xian G, Zhang J, Zeng Q. Optimal Antithrombotic Therapy for Patients with STEMI Undergoing PCI at High Risk of Bleeding. Curr Atheroscler Rep. 2019 Apr 17;21(6):22. doi: 10.1007/s11883-019-0782-x. PMID: 30997584. 10: Arcinas LA, Manji RA, Hrymak C, Dao V, Sheppard JI, Warkentin TE. Autoimmune heparin-induced thrombocytopenia and venous limb gangrene after aortic dissection repair: in vitro and in vivo effects of intravenous immunoglobulin. Transfusion. 2019 Jun;59(6):1924-1933. doi: 10.1111/trf.15263. Epub 2019 Mar 23. PMID: 30903805. 11: Kołtowski Ł, Legutko J, Filipiak KJ, Dziewierz A, Bartuś S, Buszman P, Buszman P, Ciećwierz D, Dąbrowski M, Dobrzycki S, Gil R, Gorący J, Grygier M, Jaguszewski M, Kochman J, Kubica J, Kuliczkowki W, Lodziński P, Ochała A, Reczuch K, Witkowski A, Wojakowski W, Wójcik J, Dudek D. Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society. Cardiol J. 2019;26(1):1-7. doi: 10.5603/CJ.2019.0029. PMID: 30882184. 12: Machado PA, Carneiro MPD, Sousa-Batista AJ, Lopes FJP, Lima APCA, Chaves SP, Sodero ACR, de Matos Guedes HL. Leishmanicidal therapy targeted to parasite proteases. Life Sci. 2019 Feb 15;219:163-181. doi: 10.1016/j.lfs.2019.01.015. Epub 2019 Jan 11. PMID: 30641084. 13: Laine M, Lemesle G, Dabry T, Panagides V, Peyrol M, Paganelli F, Bonello L. Bivalirudin during percutaneous coronary intervention in acute coronary syndromes. Expert Opin Pharmacother. 2019 Feb;20(3):295-304. doi: 10.1080/14656566.2018.1551361. Epub 2018 Dec 4. PMID: 30513232. 14: van Gameren M, Lemmert ME, Wilschut JM, Daemen J, De Jaegere PPT, Zijlstra F, Van Mieghem NMDA, Diletti R. An update on the use of anticoagulant therapy in ST-segment elevation myocardial infarction. Expert Opin Pharmacother. 2018 Sep;19(13):1441-1450. doi: 10.1080/14656566.2018.1512583. Epub 2018 Sep 5. PMID: 30185087. 15: Wong CK, White HD. In the transition from fibrinolysis to primary PCI, the HERO trials help refine STEMI ECG interpretation and Q wave analysis potentially alters future management. Eur Heart J Acute Cardiovasc Care. 2020 Mar;9(1_suppl):26-33. doi: 10.1177/2048872618795513. Epub 2018 Aug 17. PMID: 30117751. 16: Zhang J, Lan N. Hirudin variants production by genetic engineered microbial factory. Biotechnol Genet Eng Rev. 2018 Oct;34(2):261-280. doi: 10.1080/02648725.2018.1506898. Epub 2018 Aug 10. PMID: 30095033. 17: Nührenberg TG, Hochholzer W, Mashayekhi K, Ferenc M, Neumann FJ. Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials. Clin Res Cardiol. 2018 Sep;107(9):807-815. doi: 10.1007/s00392-018-1251-1. Epub 2018 Apr 13. PMID: 29654437. 18: Cavallari I, Patti G. Clinical effects with inhibition of multiple coagulative pathways in patients admitted for acute coronary syndrome. Intern Emerg Med. 2018 Oct;13(7):1019-1028. doi: 10.1007/s11739-018-1834-x. Epub 2018 Mar 21. PMID: 29564693. 19: Zaleski KL, DiNardo JA, Nasr VG. Bivalirudin for Pediatric Procedural Anticoagulation: A Narrative Review. Anesth Analg. 2019 Jan;128(1):43-55. doi: 10.1213/ANE.0000000000002835. PMID: 29461391. 20: Vakili B, Nezafat N, Negahdaripour M, Yari M, Zare B, Ghasemi Y. Staphylokinase Enzyme: An Overview of Structure, Function and Engineered Forms. Curr Pharm Biotechnol. 2017;18(13):1026-1037. doi: 10.2174/1389201019666180209121323. PMID: 29424308.